Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Shimada

Showing results (161-170 of 295) with videos related to

Pageof 30
Sort By:
British Journal of Cancer|March 23, 2016
Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodiesNaoki Takahashi, Satoru Iwasa, Hirokazu Taniguchi, et al.
International Journal of Clinical Oncology|October 27, 2009
Current therapeutic strategies for anal squamous cell carcinoma in JapanAtsuo Takashima, Yasuhiro Shimada, Tetsuya Hamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)Atsushi Ohtsu, Yasuhiro Shimada, Kuniaki Shirao, et al.
Anticancer Research|June 30, 2016
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal CancerToshifumi Yamaguchi, Satoru Iwasa, Kengo Nagashima, et al.
Japanese Journal of Clinical Oncology|November 6, 2020
Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG1702AKiyo Tanaka, Gakuto Ogawa, Junki Mizusawa, et al.
Japanese Journal of Clinical Oncology|October 10, 2009
Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilitiesKazutaka Kikuta, Masahiro Gotoh, Tatsuo Kanda, et al.
BMC Research Notes|April 30, 2014
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancerNaoki Takahashi, Yasuhide Yamada, Hirokazu Taniguchi, et al.
Japanese Journal of Clinical Oncology|November 9, 2012
A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruptionHironobu Hashimoto, Satoru Iwasa, Takako Yanai, et al.
Japanese Journal of Clinical Oncology|June 23, 2012
Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumourDaisuke Kubota, Taketo Okubo, Tsuyoshi Saito, et al.
Japanese Journal of Clinical Oncology|September 10, 2011
Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilitiesDaisuke Kubota, Hajime Orita, Akihiko Yoshida, et al.
Pageof 30

Showing results (161-170 of 295) with videos related to

Sort By:
Pageof 30
British Journal of Cancer|March 23, 2016
Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodiesNaoki Takahashi, Satoru Iwasa, Hirokazu Taniguchi, et al.
International Journal of Clinical Oncology|October 27, 2009
Current therapeutic strategies for anal squamous cell carcinoma in JapanAtsuo Takashima, Yasuhiro Shimada, Tetsuya Hamaguchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2002
Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205)Atsushi Ohtsu, Yasuhiro Shimada, Kuniaki Shirao, et al.
Anticancer Research|June 30, 2016
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal CancerToshifumi Yamaguchi, Satoru Iwasa, Kengo Nagashima, et al.
Japanese Journal of Clinical Oncology|November 6, 2020
Second primary cancers and recurrence in patients after resection of colorectal cancer: An integrated analysis of trials by Japan Clinical Oncology Group: JCOG1702AKiyo Tanaka, Gakuto Ogawa, Junki Mizusawa, et al.
Japanese Journal of Clinical Oncology|October 10, 2009
Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilitiesKazutaka Kikuta, Masahiro Gotoh, Tatsuo Kanda, et al.
BMC Research Notes|April 30, 2014
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancerNaoki Takahashi, Yasuhide Yamada, Hirokazu Taniguchi, et al.
Japanese Journal of Clinical Oncology|November 9, 2012
A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruptionHironobu Hashimoto, Satoru Iwasa, Takako Yanai, et al.
Japanese Journal of Clinical Oncology|June 23, 2012
Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumourDaisuke Kubota, Taketo Okubo, Tsuyoshi Saito, et al.
Japanese Journal of Clinical Oncology|September 10, 2011
Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilitiesDaisuke Kubota, Hajime Orita, Akihiko Yoshida, et al.
Pageof 30